Lenvatinib Versus Sorafenib as First‐Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis

BACKGROUND: In a global, phase III, open‐label, noninferiority trial (REFLECT), lenvatinib demonstrated noninferiority to sorafenib in overall survival and a statistically significant increase in progression‐free survival in patients with unresectable hepatocellular carcinoma (HCC). Recently, lenvat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Kim, John J., McFarlane, Thomas, Tully, Stephen, Wong, William W.L.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Health Outcomes and Economics of Cancer Care
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066720/
https://ncbi.nlm.nih.gov/pubmed/32162815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0501
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars